Michael Barbella, Managing Editor06.07.23
Ora Inc. has named Paul Colvin as chief operating officer (COO), reporting directly to Chairman/CEO Stuart Abelson.
“Paul is an operating executive with a proven track-record of managing large complex businesses. His patient focused, service-minded approach directly aligns with Ora’s mission to serve ophthalmology innovators around the world,” Ableson said. “In his role as COO, Paul will lead Ora’s continued global growth through focus on scaling Ora’s people, processes and technologies with the operational excellence, high quality, scientific rigor and white-glove customer service for which Ora is known.”
With more than 30 years of experience building and leading global teams in both pharmaceuticals and pharma services, Colvin began his career as a pharmacist and then spent 14 years with Eli Lilly in increasing roles of responsibility in the United States, Europe, and Asia. Recruited by PPD, he spent 12 years leading its clinical development business. In 2018 he joined Syneos Health as president of clinical development solutions and was later promoted to chief business officer in 2021.
“Ora’s deep therapeutic knowledge, relationships in the ophthalmology ecosystem, understanding of the patient’s journey, standardized scales, disease models, regulatory experience and unique patient enrollment techniques allow Ora to deliver value to clients and the patients they serve,” Colvin stated. “Ora’s focus on culture and people has created a stable and talented team with an unmatched track-record for helping clients achieve success.”
Ora is a full-service ophthalmic drug and device development firm with offices in North America, South America, Europe, Australia, and Asia. For more than 45 years, the firm has helped clients earn more than 82 product approvals. It supports a wide array of organizations, from startups to global pharmaceutical and device companies, to efficiently bring new products from concept to market. Ora's pre-clinical and clinical models, methodologies, and global regulatory strategies have been refined and proven across thousands of global projects. Ora bring together the world's most extensive and experienced team of ophthalmic experts, R&D professionals, and management executives to maximize the value of new product initiatives.
“Paul is an operating executive with a proven track-record of managing large complex businesses. His patient focused, service-minded approach directly aligns with Ora’s mission to serve ophthalmology innovators around the world,” Ableson said. “In his role as COO, Paul will lead Ora’s continued global growth through focus on scaling Ora’s people, processes and technologies with the operational excellence, high quality, scientific rigor and white-glove customer service for which Ora is known.”
With more than 30 years of experience building and leading global teams in both pharmaceuticals and pharma services, Colvin began his career as a pharmacist and then spent 14 years with Eli Lilly in increasing roles of responsibility in the United States, Europe, and Asia. Recruited by PPD, he spent 12 years leading its clinical development business. In 2018 he joined Syneos Health as president of clinical development solutions and was later promoted to chief business officer in 2021.
“Ora’s deep therapeutic knowledge, relationships in the ophthalmology ecosystem, understanding of the patient’s journey, standardized scales, disease models, regulatory experience and unique patient enrollment techniques allow Ora to deliver value to clients and the patients they serve,” Colvin stated. “Ora’s focus on culture and people has created a stable and talented team with an unmatched track-record for helping clients achieve success.”
Ora is a full-service ophthalmic drug and device development firm with offices in North America, South America, Europe, Australia, and Asia. For more than 45 years, the firm has helped clients earn more than 82 product approvals. It supports a wide array of organizations, from startups to global pharmaceutical and device companies, to efficiently bring new products from concept to market. Ora's pre-clinical and clinical models, methodologies, and global regulatory strategies have been refined and proven across thousands of global projects. Ora bring together the world's most extensive and experienced team of ophthalmic experts, R&D professionals, and management executives to maximize the value of new product initiatives.